Biomaterials assist radioimmunotherapy in combination to inhibit tumor metastasis or have a breakthrough July 27, 2018 Source: Health News How to effectively eliminate primary tumors, inhibit tumor metastasis and even prevent tumor recurrence? Recently, Professor Liu Zhuang from the Institute of Functional Nano and Soft Materials of Soochow University and Associate Professor Yang Kai of the School of Radiation Medicine and Protection published an article in Nature·Biomedical Engineering, reporting a radioimmunotherapy based on biomaterials. The new strategy is expected to be a breakthrough in inhibiting tumor metastasis and recurrence. In this study, a therapeutically useful radioisotope iodine 131 was labeled on catalase, which was then uniformly mixed with the immunoadjuvant CpG and sodium alginate to obtain a composite injection. In this system, catalase can efficiently decompose endogenous hydrogen peroxide between tumor tissues to produce oxygen, enhance the efficacy of radiotherapy by improving tumor hypoxia; CpG can correlate tumors with residual tumors after internal radiotherapy The antigen interacts to produce a tumor-specific immune response; after local injection into the tumor, sodium alginate can bind to calcium ions in the interstitial fluid of the tumor cells and rapidly form a gel, and immobilize the iodine 131-labeled catalase on the tumor. Within, enhance its catalytic effect while reducing the radiation side effects on normal organs. Studies have shown that this strategy can completely kill in situ solid tumors in a mouse tumor model, a human xenograft model, and a rabbit tumor model at a lower dose of radioactivity, and further trigger an anti-tumor immune response. . By using an immunological checkpoint inhibitor, the body's own immune system can be used to pursue the distantly transferred tumor cells, thereby effectively inhibiting tumor metastasis. The researchers also observed a vaccine-like immune memory effect that protects mice from tumor recurrence. Radiation therapy is usually used to treat local solid tumors, and it is difficult to effectively kill the diffuse tumor lesions after metastasis. This study mainly destroys visible solid tumors by enhancing internal radiotherapy, further triggers the body's own immune response, eliminates metastatic tumor lesions, and prevents recurrence. This strategy is expected to be applied to the treatment of many types of solid tumors, providing opportunities for advanced patients who have undergone tumor metastasis and cannot be cured by surgery or chemotherapy. All reagents used in this strategy are based on natural biomaterials and have good biocompatibility. The Liuzhuang team is currently working to bring such biomaterial-based radioimmunotherapy strategies to clinical transformation. (Correspondent Yang Shuting Ding Wei special correspondent Shen Dalei) Tetanus Vaccine,Hepatitis B Vaccine For Adults,Tetanus Booster,Td Vaccine FOSHAN PHARMA CO., LTD. , https://www.foshanpharma.com